semaglutide
Semaglutide vs. Tirzepatide: Head‑to‑Head Data, Real‑World Stories, and What It Means for Obesity Care
Tirzepatide Achieves 22% Mean Weight Loss in SURMOUNT-2 - Setting a New Benchmark In the 72-week SURMOUNT-2 trial, participants on tirzepatide 15 mg shed an average of 22% of their baseline weight, eclipsing the 15% loss seen with the best-in-class GLP-1 agonist, semaglutide. The study, published in 2024, also reported